Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2155925 | 0.86 | CYP3A4 (0.39) | PRKCANR3C2CYP3A4 | |
| SCHEMBL2156037 | 0.82 | PRKCA (0.36) | PRKCANR3C2 | |
| SCHEMBL2155906 | 0.78 | SIRT2 (0.34) | SIRT2 | |
| SCHEMBL2156979 | 0.72 | PRKCA (0.44) | PRKCACYP3A4 | |
| SCHEMBL4622838 | 0.70 | SIRT2 (0.35) | SIRT2 | |
| SCHEMBL2155857 | 0.70 | CYP3A4 (0.43) | CYP3A4 | |
| SCHEMBL2156923 | 0.68 | TSHR (0.39) | PRKCACYP3A4 | |
| SCHEMBL2155251 | 0.65 | ALDH1A1 (0.36) | PRKCA | |
| SCHEMBL17926642 | 0.63 | ALDH1A1 (0.39) | — | |
| SCHEMBL17926662 | 0.62 | HTT (0.44) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161352-A1 | Substituted Benzo-Condensed Cycloheptanone Derivatives and the Use Thereof for Medicament Production | GRUENENTHAL GMBH (DE) | 2008-07-03 | — | — | US | claimed |
| US-7973072-B2 | Pain, eating disorders, neurodegenerative disorders, memory impairment; attention deficit syndrome, opioid tolerance, drug addiction; (4-oxothiochroman-3,3-diyl)bis(methylene)bis(3-(trifluoromethyl)benzoate for example | GRUENENTHAL GMBH (DE) | 2011-07-05 | — | — | US | disclosed |
| US-7973072-B2 | Pain, eating disorders, neurodegenerative disorders, memory impairment; attention deficit syndrome, opioid tolerance, drug addiction; (4-oxothiochroman-3,3-diyl)bis(methylene)bis(3-(trifluoromethyl)benzoate for example | GRUENENTHAL GMBH (DE) | 2011-07-05 | — | — | US | disclosed |
| US-7973072-B2 | Pain, eating disorders, neurodegenerative disorders, memory impairment; attention deficit syndrome, opioid tolerance, drug addiction; (4-oxothiochroman-3,3-diyl)bis(methylene)bis(3-(trifluoromethyl)benzoate for example | GRUENENTHAL GMBH (DE) | 2011-07-05 | — | — | US | disclosed |
| US-20080161352-A1 | Substituted Benzo-Condensed Cycloheptanone Derivatives and the Use Thereof for Medicament Production | GRUENENTHAL GMBH (DE) | 2008-07-03 | — | — | US | disclosed |
| US-20080161352-A1 | Substituted Benzo-Condensed Cycloheptanone Derivatives and the Use Thereof for Medicament Production | GRUENENTHAL GMBH (DE) | 2008-07-03 | — | — | US | disclosed |
| US-20080161352-A1 | Substituted Benzo-Condensed Cycloheptanone Derivatives and the Use Thereof for Medicament Production | GRUENENTHAL GMBH (DE) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161352-A1 | Substituted Benzo-Condensed Cycloheptanone Derivatives and the Use Thereof for Medicament Production | BCKDK, SYMPK, DHPS | PRKCA 4328/4885SIRT2 1043/4885NR3C2 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.